de Wit, Ronald http://orcid.org/0000-0002-1954-090X
Freedland, Stephen J.
Oudard, Stephane
Marinov, Georgi
Capart, Philippe
Combest, Austin J.
Peterson, Ryan
Ozatilgan, Ayse
Morgans, Alicia K.
Funding for this research was provided by:
Sanofi
Article History
Received: 1 September 2021
Revised: 22 November 2021
Accepted: 13 December 2021
First Online: 17 January 2022
Competing interests
: RdW has provided a consulting or advisory role for Sanofi, Merck Sharp & Dohme, Roche/Genetech, Janssen, Bayer and Clovis Oncology, and received travel/accommodation/expenses from Lilly. RdW has received honoraria and/or research funding from Sanofi, Merck Sharp & Dohme and Bayer. SF received research funding from Pfizer and received personal fees from Pfizer, Astellas, Janssen, Bayer, Myovant, AstraZeneca, Merck, Dendreon and Sanofi. SO received honoraria from Pfizer, Bayer, Novartis, BMS, Merck, Janssen and Astellas, and received travel/accommodation/expenses from Pfizer, Bayer, Novartis, BMS, Merck, Janssen, Astellas and Sanofi. GM has received personal fees (contracted by Sanofi) from Sanofi. PC has received fees (contracted by Sanofi) from Sanofi and is employed by Medimix. AC has received fees (contracted by Sanofi) from Sanofi and as a data provider for Medimix. RP is employed by Sanofi and AO is a former employee of Sanofi. AO owns stock in Sanofi. AM has received personal fees from Janssen, Astellas, Seattle Genetics and Genentech, and received personal fees and research funding from Bayer.